Overview

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

Status:
Unknown status

Trial end date:
2004-11-01

Target enrollment:

Participant gender:

Summary

In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

Phase:

Phase 1

Details

Lead Sponsor:

National Institute on Drug Abuse (NIDA)

Treatments:

Methamphetamine
Reserpine